Obesity Treatment Firm Kailera Upsizes IPO to Raise $625 Million

Kailera Therapeutics, a biotech firm specializing in obesity treatments, upsized its IPO to raise $625 million, making it the largest US biotech listing since 2021. The company aims to advance its clinical pipeline, with the funds supporting ongoing trials and expansion plans, signaling strong investor interest in obesity-focused biotech innovations.

Chainshorts summarizes news into 60-word briefs. Full article is owned and hosted by Bloomberg Markets. Read the original via the link above. Chainshorts users earn SKR for reading in the app.